Anavex Life Sciences Corp.AVXLNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank7
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-34.08M
↓ 38% vs avg
Percentile
P7
Near historical low
Streak
1 yr
Consecutive growthContracting
Average
$-24.78M
Historical baseline
PeriodValueYoY Change
TTM$-34.08M+12.7%
2025$-39.04M-26.7%
2024$-30.81M-10.9%
2023$-27.79M-14.6%
2022$-24.24M+20.2%
2021$-30.38M-42.7%
2020$-21.29M-14.9%
2019$-18.53M-47.2%
2018$-12.58M-39.5%
2017$-9.02M-